Bessemer Group Inc. Trims Stock Position in Intuitive Surgical, Inc. $ISRG

Bessemer Group Inc. reduced its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 19.0% during the fourth quarter, Holdings Channel reports. The firm owned 783,950 shares of the medical equipment provider’s stock after selling 183,828 shares during the quarter. Intuitive Surgical makes up approximately 0.7% of Bessemer Group Inc.’s portfolio, making the stock its 25th biggest position. Bessemer Group Inc.’s holdings in Intuitive Surgical were worth $443,998,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of ISRG. Brighton Jones LLC boosted its holdings in shares of Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after buying an additional 731 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Intuitive Surgical by 3.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock valued at $504,000 after buying an additional 34 shares in the last quarter. Schnieders Capital Management LLC. boosted its holdings in shares of Intuitive Surgical by 38.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock valued at $529,000 after buying an additional 268 shares in the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Intuitive Surgical during the 2nd quarter valued at $200,000. Finally, Main Street Financial Solutions LLC boosted its holdings in shares of Intuitive Surgical by 92.4% during the 2nd quarter. Main Street Financial Solutions LLC now owns 2,929 shares of the medical equipment provider’s stock valued at $1,592,000 after buying an additional 1,407 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling

In related news, SVP Patricia L. Wadors sold 220 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $499.71, for a total value of $109,936.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Gary Loeb sold 400 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $446.95, for a total transaction of $178,780.00. Following the completion of the transaction, the executive vice president owned 6,120 shares in the company, valued at approximately $2,735,334. The trade was a 6.13% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,647 shares of company stock worth $2,760,359 over the last quarter. 0.60% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Argus dropped their target price on shares of Intuitive Surgical from $630.00 to $560.00 and set a “buy” rating on the stock in a report on Wednesday, February 4th. Evercore dropped their target price on shares of Intuitive Surgical from $550.00 to $480.00 and set a “neutral” rating on the stock in a report on Monday, April 6th. BTIG Research restated a “buy” rating and set a $574.00 target price on shares of Intuitive Surgical in a report on Wednesday, April 22nd. Barclays set a $651.00 target price on shares of Intuitive Surgical and gave the company an “overweight” rating in a report on Thursday, April 23rd. Finally, Leerink Partners dropped their target price on shares of Intuitive Surgical from $622.00 to $573.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd. Eighteen research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $581.91.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $428.06 on Friday. The stock has a market cap of $151.60 billion, a price-to-earnings ratio of 51.89, a PEG ratio of 3.45 and a beta of 1.51. The firm’s 50-day moving average is $465.23 and its 200 day moving average is $514.69. Intuitive Surgical, Inc. has a 1 year low of $417.74 and a 1 year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.08 by $0.42. The company had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. Intuitive Surgical’s revenue was up 23.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.81 EPS. On average, equities analysts expect that Intuitive Surgical, Inc. will post 8.57 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.